Purpose: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer retinal layers outside the macula after intravitreal ocriplasmin injection. To study the relation between vitreous detachment and attenuation of retinal outer segments signal.
P hysiologically, vitreous is completely attached to the retina. 1 Posterior vitreous detachment (PVD) develops with aging because of progressive degeneration and liquefaction of the vitreous. 2 This process starts with a shallow, normally asymptomatic vitreous detachment around the macula and a concomitant persistent vitreomacular adhesion. 3 If vitreous modifications occur without a concomitant weakening of vitreomacular interface, a pathologic adhesion between posterior vitreous cortex and retinal internal limiting membrane persists. A pathologic adhesion located at the posterior pole of the eye can lead to vitreomacular traction (VMT). Vitreomacular traction causes anatomical distortion of the foveal profile and generates symptoms like decrease visual acuity and metamorphopsia. 4, 5 Patients with VMT can be managed with watchful waiting, pneumatic vitreolysis, standard vitrectomy, or intravitreal ocriplasmin injection. 6 Ocriplasmin (Jetrea; Thrombogenics USA, Alcon/ Novartis EU) is a recombinant truncated form of a protease derived from human plasmin, and it has been approved by the Food and Drug Administration as nonsurgical treatment option for symptomatic VMT and VMT associated with a macular hole (MH). It has proteolytic activity and enzymatically it cleaves the major components of the vitreomacular interface (fibronectin and laminin), inducing both vitreoretinal separation and vitreous liquefaction. 7, 8 The MIVI-TRUST Phase III trials evaluated the efficacy and safety of a single ocriplasmin injection compared with a placebo injection for the treatment of symptomatic vitreomacular adhesion and MH, and reported a 26.5% resolution of vitreomacular adhesion at Day 28 in the ocriplasmin group versus 10.1% in placebo group. 9 The safety profile of ocriplasmin included adverse events related to the intravitreal injection procedure (pain) and the induction of PVD (floaters), together with photopsias and transient reduction in visual acuity. 9 However, concerns have been raised regarding ocriplasmin ocular safety, 10 and a more detailed review of safety data reported additional adverse events that included electroretinography changes, dyschromatopsia, retinal tears and detachments, lens subluxation, retinal arteries attenuation, and disruption of the ellipsoid zone. 11, 12 A premarketing, single center, Phase II trial found that the rate of electroretinography changes after ocriplasmin injection may be up to 69%. 13 In addition, the early structural abnormalities to the photoreceptors detected with fundus autofluorescence and spectral domain optical coherence tomography (SD-OCT) have been found not only in the macular region but also in the peripheral retina. 14, 15 Spectral domain optical coherence tomography reveals the appearance of subfoveal fluid, focal areas of attenuation/thinning of ellipsoid zone with disappearance of the interdigitation zone of photoreceptors, and multifocal shallow subretinal detachments. The photoreceptor abnormalities correspond to patchy areas of increased fundus autofluorescence signal at the macula, and radial lines of abnormally increased fundus autofluorescence signal toward the retinal periphery. 15 All these data suggest that ocriplasmin retinopathy, when it occurs, is panretinal in extent.
The wide-field OCT (HRA Spectralis; Heidelberg Engineering, Heidelberg, Germany) expands the OCT field of view from 30°to 55°, allowing the visualization of the retina from the macula and the optic nerve head to the midperiphery. Wide-field OCT can be used to examine both peripheral retinal pathology and posterior pole within a single volume scan. 16 Wide-field OCT can help in the diagnosis of ocriplasmin retinopathy, and it allows the recording and monitoring of the progression of retinal and vitreous changes before and after ocriplasmin injection.
The purpose of our study was to analyze the relation between retina and vitreous from the macula to the midperiphery before and after an ocriplasmin injection. In addition, it tries to localize the presence of possible alteration of photoreceptors outer segment and their spatial distribution in the retina using widefield OCT images.
Materials and Methods
This is a retrospective study conducted at the Eye Clinic, Department of Biomedical and Clinical Science "Luigi Sacco," Sacco Hospital, University of Milan, Milan. Each patient signed informed consent. This study followed the rules of the Declaration of Helsinki of the World Medical Association and approval from the local ethical committee was obtained before the revision of data.
For the study, we reviewed charts from patients treated with intravitreal ocriplasmin injection (0.125 mg) for symptomatic VMT between April 1, 2014, and October 19, 2015. Diagnosis of VMT was performed using OCT and based on evidence of an incomplete separation of the vitreous cortex from the internal limiting membrane at the fovea, causing a macular traction with an alteration of the foveal profile associated or not with a full-thickness MH.
To be eligible, vitreoretinal adherence had to be less than 1,500 mm, as measured using OCT around the fovea. If an MH was present, diameter was measured on OCT as the shortest linear distance between the edges of the hole and it had to be less than 400 mm. No evidence of epiretinal membranes was mandatory. Inclusion criteria were in accordance with a post hoc analysis of the MIVI-TRUST trials. 9 We included patients who underwent OCT examination (HRA Spectralis; Heidelberg Engineering) using the 55°wide-field lens and for whom a complete series of 6 wide-field B-scans was available at baseline and at least 2 times during the first 6 months of follow-up. The complete series of 6 B-scans encompassed a horizontal and a vertical scan centered on the fovea and other four single scans starting from the fovea and directed to the superior, inferior, temporal, and nasal periphery. In this way, we postulated to be able to visualize a 100°vertical and horizontal section of the retina centered on the fovea (Figure 1 ). The Spectralis OCT provides up to 40,000 A-scans/s using a superluminescent diode at 870 nm. By an active eyetracking technology, the system automatically follows eye movements and locks each OCT B-scan to the fundus image. The eye-tracking technology also permits precise scanning of the same location over consecutive visits. Exclusion criteria included the presence of any pathologic condition such as glaucoma or diabetes that could have an influence on visual acuity and retinal morphology.
The intravitreal injection procedure was performed in a standard fashion. Briefly, under controlled aseptic conditions, 0.125 mg of ocriplasmin in 0.1 mL was intravitreally injected through pars plana (3.5 mm from the limbus) in the inferotemporal quadrant with a 30-gauge needle fully inserted in the sclera and directed toward the posterior pole. No paracentesis was performed in the anterior chamber of the eye. Intraocular pressure was routinely tested for 30 minutes after the injection and patients were asked to lay down for a couple of hours in a supine position before leaving the hospital.
To determine the relation between vitreous and retina, all wide-field SD-OCT scans were reviewed by two expert graders and then compared. The vitreous was considered as detached when a continuous hyperreflective line separated from the retina surface was visible throughout the scan or when it was not possible to detect any signal originated from the vitreous. 17 We defined vitreopapillary adhesion (VPA), the adherence of the vitreous to the optic nerve head surrounded by shallow vitreous detachment, as visible on the horizontal wide-field SD-OCT centered in the fovea. The OCT diagnosis of VMT and VMT associated with MH was based on the criteria of the International Vitreomacular Traction Study group. 18 The integrity or the attenuation of the ellipsoid and interdigitation zone was also determined by the two expert graders. Baseline wide-field SD-OCTs were examined and when no concordance was noted, a decision was made by a third grader. Follow-up examinations were directly compared with the baseline SD-OCT scans obtained at the same location; ellipsoid and interdigitation zones were considered attenuated when both graders recorded a reduction of the signal and intact when both recorded no signal differences compared with baseline. No statistical analysis was performed because of the small sample of patients included, this study being merely descriptive.
As standard of care in our department, patients treated with ocriplasmin were evaluated at baseline and then at 1 week, 1 month, 3 months, and 6 months after injection ( Figure 3) . During every assessment, each patient underwent a comprehensive ophthalmologic examination, including best-corrected visual acuity (BCVA), intraocular pressure measurement, slit-lamp anterior segment evaluation, fundus examination, and SD-OCT. Best-corrected visual acuity was measured using Early Treatment Diabetic Retinopathy Study charts and then converted to logarithm of the minimum angle of resolution (logMAR) for the purpose of this paper.
Results
A total of 18 patients were treated in our department with intravitreal ocriplasmin injection for symptomatic VMT between April 1, 2014, and October 19, 2015: 15 of them met the inclusion criteria and were included in this study (Table 1 ). All included eyes were phakic. The mean age of patients was 70 years (range, 45-84 years). There were 5 men and 10 women. A complete protocol of six wide-field OCT B-scan was available for all the patients at baseline, 1 week, 1 month, 3 months, and 6 months after intravitreal ocriplasmin injection. In addition, in three patients, wide-field OCT scans were obtained the first day after injection.
At baseline, 10 patients were diagnosed with VMT and 5 patients with VMT associated to an MH with aperture size less than 400 mm. In details, the holes measured 89 mm, 151 mm, 153 mm, 260 mm, and 289 mm.
No complications occurred during intravitreal injection procedure, no rising of the intraocular pressure was recorded in the early postoperative period. All the patients complied with supine positioning. No patients showed severe adverse events such as endophthalmitis or retinal detachments during the follow-up.
The mean BCVA at baseline was 0.4 logMAR (20/ 50 Snellen). Average visual acuity at Week 1 was 0.4 logMAR (20/50 Snellen), at Month 1 and 3, it was 0.3 logMAR (20/40 Snellen) and at Month 6, 0.2 logMAR (20/32 Snellen). At 6-month follow-up, 13 patients presented an increased or stationary BCVA. In two patients, a slight decrease of BCVA was reported one patient had no VMT resolution after the injection. The other, diagnosed with VMT associated with MH, underwent pars plana vitrectomy (PPV) after 3 months because the MH remained open.
At baseline, all patients (100%) presented with VPA, one patient (7%) had vitreous adherence only nasally and one patient (7%) had vitreous detached only temporally (Figure 1 ). The ellipsoid zone was intact in each scan for all the patients (100%).
After ocriplasmin injection, VMT release occurred in 12 patients (80%) and 3 of them (20%) presented with complete PVD (Figure 1 ). At 1-week follow-up, a complete resolution of the VMT was present in 10 patients with 2 of them showing resolution the first day after injection (Table 2 ). In the other two patients, VMT resolution was detected 3 months after the injection. Despite a complete resolution of the VMT, two of the patients diagnosed with VMT associated with MH underwent PPV (one at 2 weeks and one at 3 months after the injection) because of an enlargement of the holes. The other three patients with MH revealed a complete closure of the holes (after 1 week in two patients and after 1 month in one patient).
Regarding the vitreoretinal relationships outside the macula, three patients developed a complete PVD 1 week after the injection as previously mentioned. In the other nine patients with a complete resolution of the VMT, the VPA persisted till the last follow-up ( Figure  3) . A slight enlargement of the shallow PVD (never reaching the 100°limit of the scans) was also noted. In the remaining three patients with no resolution of the VMT, no changes occurred at the VPA and at the peripheral adherence between vitreous and retina.
In eight patients (53%), the wide-field OCT scans revealed an attenuation of ellipsoid and interdigitation zone that involved the posterior pole and all the quadrants (Figure 1 ): seven of them had resolution of the VMT and one showed non-PVD and no VMT resolution. In three patients with VMT resolution, the attenuation involved also areas with no PVD ( Figure  2 ). Wide-field OCT scans revealed also shallow peripheral retinal detachments in three patients ( Figure  2 ): all of them had attenuation of photoreceptor outer segment, two patients with a complete PVD, and 1 with no PVD and no VMT resolution. The attenuation of ellipsoid and interdigitation zone and the shallow peripheral retinal detachments were visible after 1 week and even 1 day after injection in available scans.
Both ellipsoid and interdigitation zone attenuation and shallow retinal detachments resolved during the followup in most patients. The attenuation of outer retinal layers disappeared in one patient after 1-month followup, in three patients after 3 months, and in one patient, 6 months after the injection (Figure 3) . The attenuation was still present at the moment of surgery in the two patients treated with PPV and it vanished at the following evaluation (at 3 and 6 months, respectively). Only in one patient, the attenuation was still visible at the last follow-up visit. All the shallow peripheral detachments disappeared within 1 month ( Table 2 ).
The mean BCVA in patients with attenuation of interdigitation and ellipsoid zone had the same trend of the patients without this complication, with a slight improvement at 1-month examination and at last follow-up. All the patients with attenuation of the ellipsoid and interdigitation zone reported a yellowish vision in the treated eye. Symptoms progressively improved during follow-up and no one reported this alteration at 6 months. In our series, no patients reported nyctalopia as symptom after ocriplasmin injection, neither in those with attenuation of ellipsoid and interdigitation zone.
Discussion
The 55°wide-field OCT imaging extends the view of the retina and helps to diagnose and manage diseases beyond the macula. Our complete wide-field 
-, patients underwent PPV; N, no; PhA, photoreceptors layer attenuation; RD, peripheral subretinal detachments; VMTr, VMT resolution; Y, yes.
OCT acquisition protocol allowed the visualization of the 100°vertical and horizontal section of the retina centered on the fovea permitting the analysis of the peripheral retinal effects of the treatment with intravitreal ocriplasmin. This is useful because even if ocriplasmin acts on a specific macular pathology, many reports in the recent literature outlined the extrafoveal effects of this treatment. 14, 15 In our study, VMT resolution occurred in 12 of 15 patients (80%): this VMT release rate is higher when compared with the results derived from the MIVI-TRUST trials (26.5%). 9 However, it is on line with more recent studies, 19, 20 where the inclusion of patients with specific baseline features resulted in higher rates of successful outcomes. Vitreomacular traction resolution was present in most patients at 1-week follow-up and in two cases, 1 day postoperatively. That is consistent with previous studies 20, 21 and it confirms that the response time to ocriplasmin injection occurs mainly within 7 days.
Despite the high rate of VMT release, a complete PVD with VPA resolution was seen only in three patients (20%) at the 1-week evaluation; three other patients presented a progressive but incomplete PVD during follow-up, with persistent VPA. The higher rate of total PVD in our study (20%) compared with the 13.4% reported in the MIVI-TRUST trials 9 is probably because of a more strict selection of patients at baseline. Our data suggest that ocriplasmin injection can infrequently induce a complete PVD but, when it happens, it occurs early during the first week. This must be an advice to carefully check the peripheral retina before and immediately after an ocriplasmin intravitreal injection: any vitreoretinal traction, degeneration, or peripheral retinal tear detected should be properly treated. Interestingly, in most patients, this drug seems to act gently removing the focal VMT with a mild effect on the peripheral adhesion of the vitreous to the retina and no VPA resolution. We can speculate that there is no VMT without VPA and the key role in the developing of a complete PVD is the adherence of the vitreous to the optic nerve. When the vitreous adhesion releases from the optic nerve, a complete PVD suddenly occurs.
As secondary effects, ocriplasmin causes symptoms and findings different from VMT release. In our samples, eight patients (53%) developed early structural abnormalities of the photoreceptor outer segments, visible as signal attenuation of the interdigitation zone and ellipsoid zone throughout the OCT scans. In three of these eight patients, we also found small peripheral retinal detachments. These functional and anatomical abnormalities seem to be due to the protease effect of ocriplasmin on intraretinal proteins such as laminin. Ocriplasmin is a very small protein with a molecular weight of 27KD. In rat eyes, it can penetrate all the retinal layers causing degradation of laminin and fibronectin at the vitreomacular interface and in the deeper retinal layers. 22 Laminin is present throughout the retina, including the outer plexiform layer (where it localizes to synapsis between photoreceptors and bipolar cells), the external limiting membrane, and the interphotoreceptor matrix. 23 The degradation and the following slow regeneration of these retinal proteins explain the reversible alteration visible in the retinal outer segment on OCT.
All these structural changes appeared early after the injection and were clearly visible at first follow-up (1 day or 1 week) in all the eight patients. When present, they were evident throughout the vertical and horizontal wide-field OCT scans. Therefore, we can postulate that alteration of the outer segments of photoreceptors induced by intravitreal ocriplasmin injection involves all the retinal quadrants and have an acute panretinal extent. Accordingly, a single-center phase 2 study described full-field electroretinography changes after ocriplasmin injection supposing a panretinal involvement of the dysfunction. 13 Interestingly, we instructed our patients to maintain a supine postoperative position (trying to increase the concentration of the drug at the posterior pole) and we noted a simultaneous fast and panretinal induction of the outer segments attenuation. As mentioned above, ocriplasmin is a small molecule probably having an easy access to the retina once settled on the internal limiting membrane. It is likely that spontaneous saccadic movements of the eye are enough to diffuse the drug into the vitreous cavity and distribute the molecules from the posterior pole to the far periphery of the retina. This may question the necessity of supine postoperative positioning and even the necessity of guided injection 24 with direct visualization of the tip of the needle during the procedure. The success rate of our series seems to suggest that it will be difficult to obtain a better outcome and definitely a very large sample size would be necessary to define the best technique between guided and not guided procedures.
We also analyzed the possible correlation between vitreous detachment and outer retinal layer alterations. Our data revealed that the attenuation was present in 8 of 12 patients with VMT resolution, including all 3 patients with complete PVD, but also peripheral retinal areas with no PVD in the other 5 patients. Attenuation was also visible in one patient with no PVD and no VMT resolution. Moreover, all the three patients with small subretinal detachments showed attenuation, two had a complete PVD and one had no PVD and no VMT release. Probably even if PVD was not induced, vitreoretinal traction can be increased by ocriplasmin injection also where vitreous is still adherent to retina. Fig. 3 . Complete 6-month follow-up of a patient treated with ocriplasmin injection for symptomatic VMT. Central 55°SD-OCT B-scan at baseline, 1 week, 1 month, 3 months, and 6 months after intravitreal ocriplasmin injection. Baseline SD-OCT (top picture) demonstrates VMT (circlet) and VPA (arrow). Optical coherence tomography signal of outer retinal layers is normal. The VMT persists until the third month follow-up (asterisk, fourth picture), where an incomplete PVD due to the persistence of VPA occurs (thick arrow, fourth picture). Few foveal intraretinial cysts are visible at last follow-up (thin arrow, bottom picture). One week after the injection, a subfoveal retinal detachment appears (arrow, second picture) and it resolves at 3-month follow-up. The attenuation of ellipsoid and interdigitation zone is visible at 1-week follow-up (arrowheads, second picture) and it persists until the 6-month follow-up, when the OCT signal is normal (arrowheads, bottom picture).
However, it seems that retinal outer segments attenuation and shallow retinal detachments are not related to vitreous detachment supporting the hypothesis that ocriplasmin can penetrate all the retinal layers causing the attenuation of photoreceptors outer segment signal. 25 Weakness of our paper is the retrospective design and the small numbers of patients included. Methodology is merely descriptive and no measurements were applied on images. Vitreoretinal relationships and photoreceptors outer segments signal were evaluated without directly measuring the grayscale intensity. All these criticism in our opinion do not affect the results.
In conclusion, to the best of our knowledge, this is the first report regarding patients treated with intravitreal injection of ocriplasmin based on wide-field OCT imaging. Looking outside the macula allowed us to visualize the attenuation of the signal of the photoreceptors outer segments and to confirm that it is a panretinal alteration. Wide-field imaging also confirms that when this alteration resolves, it is a panretinal resolution. The examination of vitreoretinal relationship of our patients suggests that ocriplasmin may act in two different ways: inducing a complete PVD (20% of the patients in our series) or gently releasing the VMT (60% of the patients in our series).
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